Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
17 Octobre 2024 - 2:00PM
Business Wire
Company to host conference call and webcast on
October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following
plenary oral presentation of data at the EORTC-NCI-AACR Symposium
(ENA) 2024
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that
it will hold an investor webcast to discuss data from a Phase 1
clinical trial of ZL-1310, the Company’s investigational
DLL3-targeted antibody-drug conjugate (ADC), in patients with
advanced stage small cell lung cancer (SCLC). The live conference
call and webcast will take place on Thursday, October 24, 2024, at
8:30 a.m. ET (8:30 p.m. HKT).
Conference Call and Webcast Information
Listeners may access the live webcast by visiting the Company's
website at http://ir.zailaboratory.com. Participants must register
in advance of the conference call.
Details are as follows:
Registration Link:
https://register.vevent.com/register/BI6f8ba8dc42d04cd3afd7095cf7c83d40
All participants must use the link provided above to complete
the online registration process in advance of the conference call.
Dial-in details will be in the confirmation email which the
participant will receive upon registering.
A replay will be available shortly after the call and can be
accessed by visiting the Company's website.
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, immunology, neuroscience, and infectious disease. Our
goal is to leverage our competencies and resources to positively
impact human health in China and worldwide.
For additional information about Zai Lab, please visit
www.zailaboratory.com or follow us at
www.twitter.com/ZaiLab_Global.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241017107131/en/
Investor Relations: Christine Chiou / Lina Zhang +1 (917)
886-6929 / +86 136 8257 6943 christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com Media: Shaun Maccoun/ Xiaoyu
Chen +1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
